...
首页> 外文期刊>Toxicology Research >Microscopic and biochemical changes on liver and kidney of Wistar rats on combination antiretroviral therapy: the impact of naringenin and quercetin
【24h】

Microscopic and biochemical changes on liver and kidney of Wistar rats on combination antiretroviral therapy: the impact of naringenin and quercetin

机译:抗逆转录病毒治疗Wistar大鼠肝肾的微观和生物化学变化:柚皮素和槲皮素的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Combination antiretroviral therapy (cART), which is a lifelong therapy for people living with human immunodeficiency virus, has been associated with nephrotoxicity and hepatotoxicity leading to its discontinuation. This study aimed at investigating the ameliorative potential of naringenin and quercetin on cART-induced hepatotoxicity and nephrotoxicity. Seventy male Wistar rats (225-260 g) were divided into seven groups as control, cART, naringenin, quercetin, dimethyl sulfoxide (DMSO), naringenin/cART (CN) and quercetin/cART (CQ). cART (24 mg/kg), naringenin (50 mg/kg) and quercetin (50 mg/kg) were dissolved in 1% v/v DMSO and administered orally for 56 days. Combination of cART and bioflavonoids had significant increase in superoxide dismutase (P < 0.05), catalase (P < 0.01), reduced glutathione (P < 0.001) and decreased malondialdehyde (P < 0.001) compared to cART only. Tumor necrosis factor Alpha (TNF alpha) level increased significantly in cART and CQ (P < 0.01) groups, while others showed no significant changes compared to control. TNF alpha also significantly decreased in CQ level compared to cART (P < 0.001). In addition, significant increase in creatinine level in cART only indicated progressive renal toxicity. Also, progressive pathological changes including congested blood vessels and hepatocellular necrosis were found in the liver, while the kidney had glomerular atrophy, and tubular distortion in cART-only group. Control, naringenin- and quercetin-treated groups showed normal renal and hepatic cytoarchitecture. These findings elucidate that progressive renal and hepatic toxicity is associated with the continuous use of cART; however, a combination of quercetin and naringenin with cART showed possible potential of ameliorating the damages posed by cART.
机译:联合抗逆转录病毒疗法(cART)是一种针对人类免疫缺陷病毒感染者的终身治疗方法,与肾毒性和肝毒性有关,导致其停药。本研究旨在研究柚皮素和槲皮素对cART诱导的肝毒性和肾毒性的改善作用。70只雄性Wistar大鼠(225-260 g)被分为7组,分别为对照组、cART、柚皮素、槲皮素、二甲基亚砜(DMSO)、柚皮素/cART(CN)和槲皮素/cART(CQ)。将cART(24 mg/kg)、柚皮素(50 mg/kg)和槲皮素(50 mg/kg)溶解在1%v/v二甲基亚砜中并口服56天。与仅使用cART相比,cART和生物类黄酮联合使用可显著增加超氧化物歧化酶(P<0.05)、过氧化氢酶(P<0.01)、还原型谷胱甘肽(P<0.001)和丙二醛(P<0.001)。cART和CQ组的肿瘤坏死因子-α(TNF-α)水平显著升高(P<0.01),而其他组与对照组相比无显著变化。与cART相比,CQ水平的TNF-α也显著降低(P<0.001)。此外,cART中肌酐水平的显著增加仅表明进行性肾毒性。此外,在cART组中,肝脏出现进行性病变,包括血管充血和肝细胞坏死,而肾脏出现肾小球萎缩和肾小管扭曲。对照组、柚皮素和槲皮素治疗组的肾和肝细胞结构正常。这些发现阐明了进行性肾和肝毒性与持续使用cART有关;然而,槲皮素和柚皮素与cART的结合显示出可能改善cART造成的损害的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号